Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
Abstract
Background Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. Objectives The objectives were to evaluate the clinical effectiveness, safety and cost-effectiveness of non-bisphosphonates {denosumab [Prolia ® ; Amgen Inc., Thousand Oaks, CA, USA], raloxifene [Evista ® ; Daiichi Sankyo Company, Ltd, Tokyo, Japan], romosozumab [Evenity ® ; Union Chimique Belge (UCB) S.A. (Brussels,...
Paper Details
Title
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
Published Date
Jun 1, 2020
Journal
Volume
24
Issue
29
Pages
1 - 314
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History